Skip to content
Inciteful Med

Standard of Care: Treating GPA

Last updated:

Treatment for Granulomatosis with polyangiitis (GPA) uses a two-phase approach: induction therapy to quickly stop active inflammation and maintenance therapy to prevent relapse. Standard medications include steroids, rituximab, cyclophosphamide, and newer steroid-sparing drugs like avacopan.

Key Takeaways

  • • GPA treatment involves a two-phase strategy: induction therapy to stop active inflammation and maintenance therapy to prevent relapse.
  • • Rituximab and cyclophosphamide are standard medications used alongside steroids to calm the overactive immune system.
  • • A newer medication called avacopan can help patients drastically reduce their reliance on long-term oral steroids.
  • • Preventative antibiotics are routinely prescribed during early treatment to protect against dangerous opportunistic infections.
  • • Emergency treatments like plasma exchange are available for severe complications such as rapid kidney failure or lung bleeding.

The treatment of Granulomatosis with polyangiitis (GPA) has evolved significantly in recent years. Doctors follow a two-phase strategy to first stop the “fire” of active inflammation and then keep it from restarting [1][2]. The ultimate goal is to achieve remission—a state where the disease is inactive—while using the lowest possible dose of medication to avoid side effects [3].

Phase 1: Induction Therapy (Stopping the “Fire”)

The first 3 to 6 months of treatment are called induction therapy [1]. This phase uses powerful medications to quickly “turn off” the overactive immune system [2][3].

  • Glucocorticoids (Steroids): Almost all patients begin with high-dose steroids (like IV methylprednisolone or oral prednisone) because they work faster than anything else to reduce immediate inflammation [4][5].
  • Rituximab (RTX): This is now a standard first-line choice for most GPA patients [1][3]. It is a biological therapy given as an intravenous (IV) infusion that targets the B cells making the harmful ANCA antibodies [6][7]. What is it like? The infusion takes a few hours. While you may feel fatigued afterward or have a mild allergic reaction, it does not cause the hair loss or extreme nausea associated with traditional chemotherapy [1].
  • Cyclophosphamide (CYC): This is a strong immunosuppressive medication used for severe cases, especially those with life-threatening kidney or lung involvement [2][6]. What is it like? Because it is a form of chemotherapy, it carries risks like hair thinning, nausea, and reduced fertility [1][2]. Importantly, it can cause bladder irritation (hemorrhagic cystitis); your doctor will likely tell you to drink plenty of fluids and may prescribe a protective medication called Mesna [2].

A New Option: Avacopan

A major breakthrough is a newer medication called avacopan [8][9]. It is a “steroid-sparing” agent. While most patients still require an initial “burst” of IV steroids to gain rapid control of the disease, avacopan can replace the prolonged, months-long oral prednisone taper [8][10]. This drastically reduces long-term steroid side effects like weight gain and bone loss [10][11].

Preventing Infections During Induction

Because induction therapy heavily suppresses your immune system, you are at risk for specific opportunistic infections [12][13]. The standard of care is to prescribe a prophylactic (preventative) antibiotic, most commonly trimethoprim-sulfamethoxazole (Bactrim), to prevent a dangerous lung infection called Pneumocystis jirovecii pneumonia (PCP) [13].

Phase 2: Maintenance Therapy (Keeping the “Fire” Out)

Once in remission, you move into maintenance therapy, which typically lasts 24 to 48 months [14]. This phase uses milder medications to prevent a relapse [3].

  • Rituximab: Given as periodic maintenance infusions, it is superior to older oral medications for keeping GPA in remission [14][15].
  • Oral Medications: Daily pills like azathioprine or methotrexate may be used if rituximab is not an option [15][16].

Plasma Exchange (Plasmapheresis)

In emergencies—such as when the kidneys are failing rapidly or there is bleeding in the lungs (alveolar hemorrhage)—doctors may use plasma exchange [17][18]. This process filters your blood through a machine to physically remove the harmful ANCA antibodies [17][19].

Timeline: What to Expect

Many patients wonder how quickly they will feel better. While everyone is different, the high-dose steroids usually improve severe fatigue and joint pain within days [4]. Sinus crusting and cough often begin to resolve within the first 2-4 weeks of induction therapy, though full remission of organ inflammation takes several months [1][3].

Frequently Asked Questions

What is the first step in treating Granulomatosis with polyangiitis (GPA)?
The first step is induction therapy, which aims to quickly stop active inflammation. This phase typically lasts three to six months and uses high-dose steroids combined with powerful medications like rituximab or cyclophosphamide.
How quickly will I feel better after starting GPA treatment?
High-dose steroids often improve severe fatigue and joint pain within a few days. Sinus crusting and coughing typically start to get better in two to four weeks, though full remission takes several months.
What is avacopan and why is it used for GPA?
Avacopan is a newer medication that helps reduce the need for long-term oral steroids. It helps control the disease while lowering the risk of steroid-related side effects like weight gain and bone loss.
Why do I need to take antibiotics during my GPA induction therapy?
Induction medications heavily suppress your immune system, putting you at risk for specific infections. Doctors prescribe preventative antibiotics, like Bactrim, to protect you from a dangerous lung infection called PCP.
What happens after my GPA goes into remission?
Once the disease is inactive, you will transition to maintenance therapy for 24 to 48 months. This phase uses milder daily pills or periodic rituximab infusions to keep the disease from relapsing.

Questions for Your Doctor

  • • Which induction therapy—rituximab or cyclophosphamide—is better for my specific organ involvement and future health goals?
  • • Am I a candidate for avacopan to help reduce the amount of prednisone I need to take?
  • • What prophylactic antibiotic will I be prescribed to prevent infections like PCP pneumonia during my induction therapy?
  • • What is the long-term plan for maintenance therapy, and how long do you expect me to stay on it?
  • • If my kidney function or lung symptoms worsen suddenly, what is our plan for emergency treatment like plasma exchange?
  • • What are the specific side effects I should watch for with my induction medication?

Questions for You

  • • How do I feel about the potential side effects of long-term steroid use (like weight gain or mood changes)?
  • • Do I have a way to track my medication schedule and any new symptoms that arise during the induction phase?
  • • Have I discussed my future plans for having children with my doctor, as some GPA treatments can affect fertility?
  • • What is my goal for 'remission'—is it getting back to work, exercise, or simply feeling like myself again?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Targeted immunotherapy strategies in ANCA-associated vasculitis.

    Puéchal X

    Joint bone spine 2019; (86(3)):321-326 doi:10.1016/j.jbspin.2018.09.002.

    PMID: 30201478
  2. 2

    Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Evolving Concepts in Treatment.

    Lynch JP, Derhovanessian A, Tazelaar H, Belperio JA

    Seminars in respiratory and critical care medicine 2018; (39(4)):434-458 doi:10.1055/s-0038-1660874.

    PMID: 30404111
  3. 3

    ANCA-Associated Vasculitic Neuropathies: A Review.

    Koike H, Nishi R, Ohyama K, et al.

    Neurology and therapy 2022; (11(1)):21-38 doi:10.1007/s40120-021-00315-7.

    PMID: 35044596
  4. 4

    [Cortisone-free rheumatology-Vasculitides].

    Holle JU, Moosig F

    Zeitschrift fur Rheumatologie 2021; (80(4)):314-321 doi:10.1007/s00393-021-00974-9.

    PMID: 33709164
  5. 5

    Drug-induced liver injury due to avacopan improved by mycophenolate mofetil: A case report.

    Yamashita R, Izumi Y, Takane K, et al.

    Medicine 2025; (104(15)):e42121 doi:10.1097/MD.0000000000042121.

    PMID: 40228281
  6. 6

    Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis.

    Falde SD, Fussner LA, Tazelaar HD, et al.

    The Lancet. Rheumatology 2024; (6(5)):e314-e327 doi:10.1016/S2665-9913(24)00035-3.

    PMID: 38574742
  7. 7

    ANCA-Associated Vasculitis: Core Curriculum 2020.

    Geetha D, Jefferson JA

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2020; (75(1)):124-137 doi:10.1053/j.ajkd.2019.04.031.

    PMID: 31358311
  8. 8

    [Pharmacological and clinical profiles of avacopan (TAVNEOS® capsule), a selective C5a receptor antagonist].

    Maruyama Y, Yoshida T, Maruyama I

    Nihon yakurigaku zasshi. Folia pharmacologica Japonica 2023; (158(5)):399-407 doi:10.1254/fpj.22161.

    PMID: 37460300
  9. 9

    Avacopan: First Approval.

    Lee A

    Drugs 2022; (82(1)):79-85 doi:10.1007/s40265-021-01643-6.

    PMID: 34826105
  10. 10

    Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide.

    Geetha D, Neumann T, Karras A, et al.

    RMD open 2025; (11(4)) doi:10.1136/rmdopen-2025-005743.

    PMID: 41052893
  11. 11

    Safety of Avacopan for the Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Combined Data From Three Clinical Trials.

    Merkel PA, George MD, Yue H, et al.

    ACR open rheumatology 2025; (7(4)):e70001 doi:10.1002/acr2.70001.

    PMID: 40192160
  12. 12

    Delta Neutrophil Index Is Associated with Vasculitis Activity and Risk of Relapse in ANCA-Associated Vasculitis.

    Yoo J, Ahn SS, Jung SM, et al.

    Yonsei medical journal 2018; (59(3)):397-405 doi:10.3349/ymj.2018.59.3.397.

    PMID: 29611402
  13. 13

    Risk factors for cytomegalovirus infection in patients with antineutrophil cytoplasmic antibody-associated vasculitis.

    Morishita M, Sada KE, Matsumoto Y, et al.

    PloS one 2019; (14(7)):e0218705 doi:10.1371/journal.pone.0218705.

    PMID: 31291263
  14. 14

    [How do I treat ANCA vasculitis with renal involvement].

    Crucil M, Regnier C, Von Frenckell C, et al.

    Revue medicale de Liege 2025; (80(9)):556-562.

    PMID: 40931730
  15. 15

    Remission maintenance in ANCA-associated vasculitis: does one size fit all?

    Berti A, Specks U

    Expert review of clinical immunology 2019; (15(12)):1273-1286 doi:10.1080/1744666X.2020.1693260.

    PMID: 31762340
  16. 16

    Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.

    Maritati F, Alberici F, Oliva E, et al.

    PloS one 2017; (12(10)):e0185880 doi:10.1371/journal.pone.0185880.

    PMID: 29016646
  17. 17

    Plasma exchange for the management of ANCA-associated vasculitis: the con position.

    Specks U, Fussner LA, Cartin-Ceba R, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2021; (36(2)):231-236 doi:10.1093/ndt/gfaa312.

    PMID: 33374017
  18. 18

    Plasma exchange in ANCA-associated vasculitis: the pro position.

    Kronbichler A, Shin JI, Wang CS, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2021; (36(2)):227-231 doi:10.1093/ndt/gfaa311.

    PMID: 33374018
  19. 19

    Plasma Exchange in ANCA-Associated Vasculitis: A Narrative Review.

    Tsiakas S, Marinaki S, Lionaki S, Boletis J

    Journal of clinical medicine 2021; (10(21)) doi:10.3390/jcm10215154.

    PMID: 34768675

This page explains standard treatments for Granulomatosis with polyangiitis (GPA) for educational purposes. Always consult your healthcare provider or specialist to discuss the best treatment plan for your specific situation.

Stay up to date

Get notified when new research about Granulomatosis with polyangiitis is published.

No spam. Unsubscribe anytime.